Go Back This article was viewed 171 times

Editorial


If tumor changes the tune, we change the music

Divyesh G. Mehta1,2,3Radhika A. Vaishnav4,5
1Division of Hematology Oncology, 2Department of Medicine, 3University of Arizona College of Medicine, Department of Medicine, Craighton University Medical School, Phoenix, USA, 4Department of Clinical Research, Research Director, Vadodara Stroke Center, Vadodara, Gujarat, India, 5Department of Life Sciences, Director, Natureka Life Sciences, Vadodara, Gujarat, India
Corresponding Author:

Radhika A. Vaishnav

Department of Clinical Research, Research Director, Vadodara Stroke Center, Vadodara, Gujarat, India, Department of Life Sciences, Director, Natureka Life Sciences, Vadodara, Gujarat, India
E-mail: radhikavaishnav@gmail.com

Corresponding Author:

Radhika A. Vaishnav

Department of Clinical Research, Research Director, Vadodara Stroke Center, Vadodara, Gujarat, India, Department of Life Sciences, Director, Natureka Life Sciences, Vadodara, Gujarat, India
E-mail: radhikavaishnav@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20184339

ABSTRACT


Last decade saw arrival of Immunotherapies and dramatic advances with PD inhibitor and CLTA4 manipulators. Now come dramatic reports of Adaptive Cell Technology, a treatment using patients own lymphocytes with anti tumor activity, expanded in vitro and reinfused. Recently, in a new clinical trial by Zakaris et al, a 49 year old patient with ER positive and ERBB2 tyrosine kinase 2 negative metastatic breast cancer that was no longer responsive to other treatments was reported to show complete regression of the cancer using Adaptive Cell Technology.
Keywords: Breast cancer, Immunotherapy, Adaptive cell technology, Cure